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The global effort to eradicate polio has become the largest
public health initiative in history and is spearheaded by the
World Health Organization, Rotary International, the
Centers for Disease Control and Prevention, and UNICEF
(United Nations Children’s Fund). During 1999, extraordi-
nary progress continued, with the number of polio-endemic
countries declining to 30 from 50 in 1998. Of the three
poliovirus types, poliovirus type 2 has reached the verge of
extinction, with the only known remaining foci existing in
northern India. Polio incidence declined to the lowest levels
ever in 1999, although the number of reported cases (7,012)
increased slightly due to improvements in surveillance and
polio outbreaks in Angola and Iraq. Existing challenges in the
initiative include maintaining effective activities, gaining
access to children in conflict-affected countries, and
sustaining political and financial support until certification is
achieved in 2005. Maintaining sufficient supplies of oral polio
vaccine emerged as an additional challenge during 1999,
resulting from marked acceleration of immunization
activities. The public-private sector partnership supporting
the initiative expanded in 1999 to include the Bill and
Melinda Gates Foundation, Ted Turner’s United Nations
Foundation, the World Bank, Aventis Pasteur, and De Beers.
Cessation of Polio Vaccination
Following certification of polio eradication by the year
2005 or shortly thereafter, the public health community and
policy makers will be faced with the decision of how and when
to stop polio vaccination. The benefits of ceasing vaccination
are well defined (i.e., annual savings of U.S. $1.5 billion in
direct global vaccination costs; the possibility of directing
these savings to other health priorities; and eradication of
vaccine-associated paralytic poliomyelitis cases). The risks
are obvious. If poliovirus is reintroduced into a susceptible
population, a catastrophic epidemic of paralytic disease,
disability, and death could ensue. Poliovirus could reemerge
through 1) reintroduction of poliovirus from a laboratory;
2) prolonged replication in immunodeficient patients; and
3) persistent transmission of vaccine-derived virus in
populations. The probability of vaccine-derived poliovirus
remaining in circulation is impossible to estimate directly.
However, the basic reproductive number or BRN (derived
from proportion excreting virus, duration of excretion, virus
titer in stool) for vaccine-derived poliovirus is lower than for
wild-type polioviruses (typically between 2 and 5 in
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industrialized countries and 10 and 15 under conditions of
poor hygiene in tropical countries). Additional data exist
from outbreak investigations, molecular sequencing of
polioviruses, and studies of poliovirus persistence
following mass vaccination campaigns (e.g., Hungary,
Finland, and Cuba). Although the currently available data
are encouraging (i.e., decreasing BRN and 3 to 6 months’
duration of circulation), substantial gaps in knowledge still
exist, including the probability of continued virus circulation
in populations with poor hygiene. These gaps need to be
addressed to ensure that the best available scientific data will
be available for decision-making.
Laboratory Containment of Wild Polioviruses
Global documentation of laboratory containment of
materials infected or potentially infected with wild poliovirus
is a key component in the decision to stop vaccination. The last
smallpox case occurred not in Somalia in 1977, but in England
in 1978. The virus was transmitted through a faulty
ventilation system from a laboratory to a nearby office, where
it infected a person. Like smallpox virus, the only remaining
sources of wild virus will be in the laboratories once the virus
has been eradicated from the natural environment. The
reported transmission of wild poliovirus from a vaccine
production facility, presumably through an infected worker,
to the community underscores the need for increased
containment once wild poliovirus has been eradicated (1).
Infectious or potentially infectious poliovirus materials
may be present in a wide range of laboratories, including
clinical diagnostic, environmental, research, and teaching.
The types of materials that might contain wild poliovirus
include clinical (e.g., diagnostic specimens or unidentified
enteroviruslike isolates), research (e.g., wild poliovirus
strains or derivatives, full-length poliovirus RNA, or cDNA
containing full capsid sequences), and environmental
(sewage). Because of its high rate of subclinical infections,
poliovirus may be found in fecal specimens collected for other
purposes. For example, fecal or sewage samples collected in
polio-endemic countries for nutritional and environmental
studies or studies of other viral, bacterial, or parasitic
diseases may contain wild poliovirus.
The WHO Global Action Plan for Laboratory Contain-
ment of Wild Polioviruses (2) was published in 1999. The plan
is linked to the eradication progress. In the preeradication
phase (the present), laboratories are required to implement
safe handling procedures for materials infected or potentially
infected with poliovirus (biosafety level [BSL] 2/polio).
Countries must establish national inventories of laboratories
holding such materials. Completion of preeradication
activities is required before a region can be certified polio-free.Conference Panel Summaries
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The posteradication phase (high containment) begins 1 year
after identification of the world’s last case. At that time,
laboratories holding wild poliovirus stocks and potentially
infectious materials must either place all materials under
appropriate biosafety conditions, transfer important virus
isolates to WHO interim repositories, or render all wild
poliovirus materials noninfectious. Documentation of con-
tainment compliance by all regions is required for global
certification of poliovirus eradication. For countries that
intend to stop all poliovirus vaccination, work with materials
that could cause infection with wild poliovirus must be
conducted under BSL 4 containment. High containment (BSL 3/
polio) will be required for work with vaccine-derived viruses.
High-level political involvement and multi-sector commit-
ments, including departments of health, defense, education,
environment, and private industry are essential to achieving
and maintaining global containment of wild poliovirus.
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Over 300 infectious diseases occur and are challenged by
over 250 drugs and vaccines. Fifteen hundred species of
pathogenic bacteria, viruses, parasites, and fungi have been
described, and printed media can no longer keep up with the
dynamics of diseases, outbreaks, and epidemics in “real time.”
Although electronic media have given us unlimited
information access, the search for meaningful data is
confusing and time-consuming. Global Infectious Diseases
and Epidemiology Network (GIDEON) is a computer software
program that was developed for disease simulation and
informatics in the fields of geographic and travel medicine.
GIDEON is currently used in 1,500 sites in 45 countries:
health ministries, military installations, travel clinics,
libraries and student teaching modules, clinical departments,
laboratories, and missionary agencies. The program consists
of four components. The first generates a Bayesian ranked
differential diagnosis based on signs, symptoms, laboratory
tests, country of origin, and incubation period and can be used
for diagnostic support and simulation of all infectious
diseases in all countries. In a blind trial conducted on 495
patients, the correct diagnosis was included in the differential
diagnosis list in 94.7% of cases (sensitivity) and displayed as
the first disease in the list in 75% (specificity).
The second component presents the epidemiology of
individual diseases, including their global effects and status
in each of 205 countries and regions. All past and current
outbreaks are described in detail, and a web-based version
under development will allow for daily updating online. The
user may also access a list of diseases related to any agent,
vector, vehicle, reservoir or country or any combination of all
five (i.e., a list of all mosquito-borne viruses of Brazil which
have an avian reservoir).
The third module is an interactive encyclopedia which
includes information on the pharmacology, use, testing
standards, and global trade names of all antiinfective drugs
and vaccines.
The fourth module is designed to identify all species of
bacteria, mycobacteria, and yeasts. The database includes 50
to 100 additional taxa that may not appear in standard texts
and laboratory databases for several months. Other options
allow the user to add data relevant to his own institution,
electronic patient charts, material from the Internet,
important telephone numbers, drug prices, antimicrobial
resistance patterns, and other information. This form of
custom data input is particularly useful when running
GIDEON on institutional networks because software
administrators can use it to disseminate and file information
relevant to their own institution for use by all computers on
their network. The data in GIDEON are derived from all peer-
reviewed journals in the fields of infectious diseases,
pediatrics, internal medicine, tropical medicine, travel
medicine, antimicrobial pharmacology, and clinical microbi-
ology; a monthly electronic literature search based on all
relevant terms in GIDEON (e.g., diseases, drugs, etc.) all
available health ministry reports (both printed and
electronic); standard texts; and abstracts of major meetings.
Further details regarding the program are available at
http://www.cyinfo.com.
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